drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified autologous T cells, CAR T cells)
drug_description
Autologous T cells engineered ex vivo to express a chimeric antigen receptor targeting BCMA (TNFRSF17); upon BCMA engagement, CAR signaling activates T-cell cytotoxicity and cytokine release to eliminate BCMA-expressing myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds BCMA (TNFRSF17); upon BCMA engagement on myeloma cells, CAR signaling activates T-cell cytotoxicity and cytokine release, leading to perforin/granzyme-mediated lysis of BCMA-expressing cells.
drug_name
SYS6020 (BCMA-targeted CAR T cells)
nct_id_drug_ref
NCT06359509